EE200100075A - 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid - Google Patents

2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid

Info

Publication number
EE200100075A
EE200100075A EEP200100075A EEP200100075A EE200100075A EE 200100075 A EE200100075 A EE 200100075A EE P200100075 A EEP200100075 A EE P200100075A EE P200100075 A EEP200100075 A EE P200100075A EE 200100075 A EE200100075 A EE 200100075A
Authority
EE
Estonia
Prior art keywords
piperidylbenzimidazole
orl
substituted
compounds
receptor agonists
Prior art date
Application number
EEP200100075A
Other languages
English (en)
Estonian (et)
Inventor
Ito Fumitaka
Noguchi Hirohide
Kondo Hiroshi
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200100075A publication Critical patent/EE200100075A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
EEP200100075A 1998-08-06 1999-07-05 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid EE200100075A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Publications (1)

Publication Number Publication Date
EE200100075A true EE200100075A (et) 2002-06-17

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100075A EE200100075A (et) 1998-08-06 1999-07-05 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid

Country Status (44)

Country Link
US (1) US6172067B1 (de)
EP (1) EP1102762B1 (de)
JP (1) JP3367945B2 (de)
CN (1) CN1317968A (de)
AP (1) AP2001002063A0 (de)
AR (1) AR018686A1 (de)
AT (1) ATE227716T1 (de)
AU (1) AU749166B2 (de)
BG (1) BG105301A (de)
BR (1) BR9912778A (de)
CA (1) CA2339621C (de)
CZ (1) CZ2001397A3 (de)
DE (1) DE69903953T2 (de)
DK (1) DK1102762T3 (de)
EA (1) EA200100104A1 (de)
EE (1) EE200100075A (de)
ES (1) ES2185357T3 (de)
GE (1) GEP20033000B (de)
GT (1) GT199900125A (de)
HK (1) HK1040188A1 (de)
HN (1) HN1999000105A (de)
HR (1) HRP20010089B1 (de)
HU (1) HUP0103567A3 (de)
ID (1) ID27212A (de)
IL (1) IL141029A0 (de)
IS (1) IS5812A (de)
MA (1) MA26659A1 (de)
NO (1) NO20010603L (de)
NZ (1) NZ509299A (de)
OA (1) OA11590A (de)
PA (1) PA8477701A1 (de)
PE (1) PE20000868A1 (de)
PL (1) PL346211A1 (de)
PT (1) PT1102762E (de)
SI (1) SI1102762T1 (de)
SK (1) SK1602001A3 (de)
SV (1) SV1999000099A (de)
TN (1) TNSN99142A1 (de)
TR (1) TR200100403T2 (de)
TW (1) TW513424B (de)
UY (1) UY25659A1 (de)
WO (1) WO2000008013A2 (de)
YU (1) YU8201A (de)
ZA (1) ZA200100900B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ATE306488T1 (de) 2000-01-05 2005-10-15 Pfizer Benzimidazol-verbindungen zur verwendung als orl1-rezeptor-antagonisten
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
WO2002040019A1 (fr) * 2000-11-15 2002-05-23 Banyu Pharmaceutical Co.,Ltd. Derives benzimidazoles
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
HUP0401333A3 (en) 2001-04-18 2004-11-29 Euro Celtique Sa Spiropyrazole compounds and pharmaceutical compositions containing them
MXPA03009602A (es) * 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
DK1975164T3 (da) 2001-04-18 2010-05-25 Euro Celtique Sa Octahydrobenzimidazolon-forbindelser som analgetika
ES2316559T3 (es) 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
EP1918279A3 (de) * 2001-04-18 2008-07-16 Euro-Celtique S.A. 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazol-2-on derivate und verwandte verbindungen als nociceptin analoge und opioid rezeptor ähnlicher rezeptor (orl1) liganden zur behandlung von schmerz
WO2003004034A1 (en) * 2001-07-02 2003-01-16 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
WO2003049736A1 (en) * 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
US8067603B2 (en) 2003-09-25 2011-11-29 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
JPWO2006038738A1 (ja) * 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
DE602006018255D1 (de) 2005-01-11 2010-12-30 Neurosearch As Neue 2-amino-benzimidazolderivate und ihre verwendung als modulatoren calciumaktivierter kaliumkanäle mit geringer leitfähigkeit
EP2043641A2 (de) * 2006-07-03 2009-04-08 NeuroSearch A/S Kombinationen aus monoamin-wiederaufnahmehemmern und kaliumkanal-aktivatoren
CN101595100B (zh) 2007-01-16 2014-06-11 普渡制药公司 作为orl-1配体的杂环取代的哌啶
EP3564240B1 (de) 2007-08-31 2022-04-06 Purdue Pharma L.P. Piperidinverbindungen als zwischenprodukte
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
AU2009275218C1 (en) 2008-07-21 2015-02-05 Purdue Pharma L.P. Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the uses thereof
EP2611784A4 (de) 2010-08-05 2014-01-08 Amgen Inc Benzimidazol- und azabenzimidazol-verbindungen zur hemmung der anaplastischen lymphomkinase
PL2800737T3 (pl) 2012-01-06 2020-11-02 Novus International Inc. Środki powierzchniowo czynne na bazie sulfotlenku
US9011832B2 (en) 2012-02-09 2015-04-21 Novus International, Inc. Heteroatom containing cyclic dimers
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
MX2015000395A (es) 2012-07-12 2015-04-10 Novus Int Inc Composiciones de matriz y capa para proteccion de bioactivos.
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
EP2976077A4 (de) 2013-03-22 2016-11-30 Scripps Research Inst Substituierte benzimidazole als nociceptin-rezeptormodulatoren
AU2015231202B9 (en) * 2014-03-20 2019-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
CN108291055B (zh) 2015-11-12 2021-07-06 诺华丝国际股份有限公司 作为溶剂的含硫化合物
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
ATE233812T1 (de) 1995-08-15 2003-03-15 Euroscreen Sa Peptide mit pronociceptiveigenschaften
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
WO1997040035A1 (en) * 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0813065A3 (de) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Regulierung von LC-132(Opioid-ähnlich)-Rezeptor-Funktion
EP0829481A1 (de) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan-Hydroxamsäure-Derivate
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
DE69826278T2 (de) 1997-05-30 2005-11-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazol-derivate
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
DK1102762T3 (da) 2002-12-16
TNSN99142A1 (fr) 2005-11-10
TR200100403T2 (tr) 2001-07-23
EA200100104A1 (ru) 2001-08-27
HRP20010089A2 (en) 2002-02-28
GEP20033000B (en) 2003-06-25
NO20010603L (no) 2001-04-05
HRP20010089B1 (en) 2003-04-30
HUP0103567A3 (en) 2003-01-28
NZ509299A (en) 2003-05-30
ES2185357T3 (es) 2003-04-16
SK1602001A3 (en) 2002-09-10
CZ2001397A3 (cs) 2002-05-15
BR9912778A (pt) 2001-09-25
ZA200100900B (en) 2002-08-28
NO20010603D0 (no) 2001-02-05
DE69903953D1 (de) 2002-12-19
PT1102762E (pt) 2003-02-28
TW513424B (en) 2002-12-11
ATE227716T1 (de) 2002-11-15
OA11590A (en) 2004-08-18
US6172067B1 (en) 2001-01-09
DE69903953T2 (de) 2003-03-27
PA8477701A1 (es) 2000-09-29
JP2002522431A (ja) 2002-07-23
JP3367945B2 (ja) 2003-01-20
MA26659A1 (fr) 2004-12-20
EP1102762A2 (de) 2001-05-30
WO2000008013A3 (en) 2000-03-23
EP1102762B1 (de) 2002-11-13
ID27212A (id) 2001-03-08
HK1040188A1 (zh) 2002-05-31
SV1999000099A (es) 2000-09-05
AP2001002063A0 (en) 2001-03-31
WO2000008013A2 (en) 2000-02-17
PE20000868A1 (es) 2000-08-31
CN1317968A (zh) 2001-10-17
IL141029A0 (en) 2002-02-10
UY25659A1 (es) 2000-02-23
IS5812A (is) 2001-01-16
GT199900125A (es) 2001-01-27
SI1102762T1 (en) 2003-04-30
PL346211A1 (en) 2002-01-28
BG105301A (en) 2001-12-29
HN1999000105A (es) 2000-11-11
HUP0103567A2 (hu) 2002-02-28
CA2339621A1 (en) 2000-02-17
AU4385999A (en) 2000-02-28
CA2339621C (en) 2005-04-05
AR018686A1 (es) 2001-11-28
YU8201A (sh) 2003-07-07
AU749166B2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
EE200100075A (et) 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid
NO20010467L (no) Ligander med høy affinitet for nociceptinreseptor ORL-1
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
ATE240341T1 (de) C-pyrazol a2a rezeptor agonisten
DK1161232T3 (da) Hydroxydiphenylureasulfonamider som IL-8-receptorantagonister
DE69926861D1 (de) Beta 2- adrenergische rezeptoragonisten
NO20013443L (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
DK2332915T3 (da) beta2-Adrenoceptoragonister
EE200200588A (et) Bensoamiidpiperidiinühendid kui substants P antagonistid
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
ATE240342T1 (de) Propargylphenyl-äther a2a rezeptoragonisten
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
DE69919171D1 (de) Muskarin-rezeptor antagonisten
ID26223A (id) Antagonis reseptor vitronektin
ID28811A (id) Antagonis reseptor vitronektin
EE200000733A (et) Tetrahüdrokinoliini derivaadid kui glütsiini antagonistid
IS5897A (is) Úreídópíperidín afleiður sem valvís NK3 viðtakamótlyf fyrir manneskjur
NO20010353D0 (no) IL-8 reseptor-antagonist
ID25461A (id) Turunan 2-ariletil-(piperidin-4-ilmetil)amina sebagai antagonis reseptor muskarinik